Recently, we came across an interesting case where Mr. A, a 26 year old Malay man with resistant schizophrenia, paranoid subtype, developed atypical antipsychotic induced obsessive-compulsive symptoms. Various attempts to treat him with conventional antipsychotics and risperidone had failed because he developed intolerable extrapyramidal side effects. Hence, he was started on clozapine. His psy...

Paranoid schizophrenia with long-term course is a challenge for the clinical and therapeutic research, particularly because chronic course is difficult to identify due to the high rate of mortality in this category of patients. The therapeutic stability on an antipsychotic molecule (haloperidol) is indeed an exception, since the current trend in the case of unfavorable course is based on therap...

PURPOSE Atypical antipsychotics (AAs), an effective treatment for schizophrenia, have a range of pharmacologic properties leading to differences in tolerability as well as heterogeneity in treatment response. Individual patient characteristics must be considered when making treatment choices, especially from an adverse event (AE) or tolerability perspective. Despite the availability of numerous...

CONTEXT Tardive dyskinesia (TD) is a common and potentially disabling disorder induced by use of antipsychotic drugs for which medical treatment often gives disappointing results. OBJECTIVE To assess the efficacy of bilateral deep brain stimulation of the internal part of the globus pallidus to treat severe TD. DESIGN Prospective phase 2 multicenter study. SETTING Six French university ho...

A depressive syndrome as identified by subjectively volunteered dysphoria occurred in 17.4% of a group of 45 DSM III-R schizophrenics, studied initially in a medication free state. Among the 24 patients who could be followed up for six months, another 25% developed depressive symptoms while on treatment. Mild depressive syndromes occurred more frequently in older patients, in association with r...

BACKGROUND AND OBJECTIVE This study assessed the safety and effectiveness of the atypical antipsychotic olanzapine for the treatment of inpatients with acute schizophrenia. Furthermore, we evaluated patterns of use of olanzapine and their relationship to safety and effectiveness. PATIENTS AND METHOD This was a prospective, comparative, nonrandomized, open-label, observational study of 848 pat...

BACKGROUND It is important to develop novel antipsychotics that can effectively treat schizophrenia with minor side-effects. The aim of our work is to develop novel antipsychotics that act on dopamine D(2) and D(3), serotonin 5-HT(1A) and 5-HT(2A) receptors with low affinity for the serotonin 5-HT(2C) and H(1) receptors, which can effectively cure positive symptoms, negative symptoms and cognit...

Paliperidone is an atypical antipsychotic medication commonly used to treat schizophrenia, schizoaffective disorder, and bipolar disorder. It a metabolite of risperidone has similar mechanism action, primarily blocking dopamine 2 receptors (D2 receptors) in the brain. various adverse effects, including extrapyramidal symptoms, weight gain, metabolic disturbances. Catatonia rare but severe side ...